Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00233974 · ClinicalTrials.gov registry record · Phase 2

Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery

A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.

Completed
Registry status
Phase 2
Development phase
15
Enrollment target

NCT00233974 is a Phase 2 study that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 15 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00233974, a Phase 2 study, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
15 participants
Enrollment target

Study Summary

RATIONALE: Comparing results of diagnostic procedures, such as molecular marker profiling, done before and after chemotherapy, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II trial is studying how well molecular marker profiling of axillary lymph nodes works in predicting response in patients with locally advanced or metastatic breast cancer who are undergoing chemotherapy followed by surgery.

Interventions

  • PROCEDURE PET (positron emission tomography)

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2002-05
Est. Completion 2006-03
Phase Phase 2

What the Registry Record Tells You About NCT00233974

The ClinicalTrials.gov registry entry for NCT00233974 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which PET (positron emission tomography) is the first listed.

NCT00233974 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00233974 about?

NCT00233974 is a clinical study titled "Molecular Marker Profiling of Axillary Lymph Nodes in Predicting Response in Patients With Locally Advanced or Metastatic Breast Cancer Who Are Undergoing Chemotherapy Followed By Surgery". RATIONALE: Comparing results of diagnostic procedures, such as molecular marker profiling, done before and after chemotherapy, may help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase II trial is studying how well molecular marker profiling of...

What is the current status of trial NCT00233974?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2002-05. Estimated completion is 2006-03.

What interventions are being tested in trial NCT00233974?

The interventions under investigation include: PET (positron emission tomography) (PROCEDURE).

Who is sponsoring clinical trial NCT00233974?

This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.